Cargando…

Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: An autopsy case

We recently reported the safety, immunological and clinical responses to a GPC3-derived peptide vaccine in a phase I clinical trial of patients with advanced hepatocellular carcinoma (HCC). We conducted a subsequent trial in advanced HCC to assess the histopathological findings before and after vacc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sawada, Yu, Yoshikawa, Toshiaki, Fujii, Satoshi, Mitsunaga, Shuichi, Nobuoka, Daisuke, Mizuno, Shoichi, Takahashi, Mari, Yamauchi, Chisako, Endo, Itaru, Nakatsura, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901810/ https://www.ncbi.nlm.nih.gov/pubmed/23466818 http://dx.doi.org/10.4161/hv.24179

Ejemplares similares

Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Cancer immunotherapy‐targeted glypican‐3 or neoantigens
por: Shimizu, Yasuhiro, et al.
Publicado: (2018)

Next-Generation Cancer Immunotherapy Targeting Glypican-3
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Identification of an H2-K(b) or H2-D(b) restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide
por: IWAMA, TATSUAKI, et al.
Publicado: (2013)

Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
por: TADA, YOSHITAKA, et al.
Publicado: ( 201)

A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012)

Peptide vaccine as an adjuvant therapy for glypican‐3‐positive hepatocellular carcinoma induces peptide‐specific CTLs and improves long prognosis
por: Taniguchi, Masatake, et al.
Publicado: (2020)

Peptide vaccines for hepatocellular carcinoma
por: Nobuoka, Daisuke, et al.
Publicado: (2013)

Higher human lymphocyte antigen class I expression in early‐stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes
por: Akazawa, Yu, et al.
Publicado: (2019)

Peptide intra-tumor injection for cancer immunotherapy: Enhancement of tumor cell antigenicity is a novel and attractive strategy
por: Nobuoka, Daisuke, et al.
Publicado: (2013)

Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes
por: SAWADA, YU, et al.
Publicado: (2014)

Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2016)

Plasma and tumoral glypican‐3 levels are correlated in patients with hepatitis C virus‐related hepatocellular carcinoma
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3
por: Kawashima, Issei, et al.
Publicado: (2015)

Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery
por: Miura, Masahiro, et al.
Publicado: (2020)

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
por: Sawada, Yu, et al.
Publicado: (2016)

Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: Two case reports
por: Suzuki, Shiro, et al.
Publicado: (2014)

Identification of glypican-3-derived long peptides activating both CD8(+) and CD4(+) T cells; prolonged overall survival in cancer patients with Th cell response
por: Sayem, Mohammad A., et al.
Publicado: (2015)

Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non–small cell lung cancer
por: Akazawa, Yu, et al.
Publicado: (2020)

Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma
por: Suzuki, Shiro, et al.
Publicado: (2016)

Extracellular miRNAs as Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma
por: Ukai, Mayu, et al.
Publicado: (2021)

Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus
por: YABUSAKI, MINA, et al.
Publicado: (2014)

Glypicans
por: Filmus, Jorge, et al.
Publicado: (2008)

Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2014)

Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2014)

Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy
por: Nobuoka, Daisuke, et al.
Publicado: (2012)

Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model
por: Fujinami, Norihiro, et al.
Publicado: (2016)

Non–clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell‐derived anti–glypican‐3 chimeric antigen receptor‐expressing natural killer/innate lymphoid cells
por: Ueda, Tatsuki, et al.
Publicado: (2020)

Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy
por: YOSHIKAWA, TOSHIAKI, et al.
Publicado: (2014)

Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery
por: Akazawa, Yu, et al.
Publicado: (2019)

Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer
por: SAWADA, YU, et al.
Publicado: (2014)

Spontaneous Tumor Lysis Syndrome in a Patient with a Dedifferentiated Endometrial Adenocarcinoma
por: Harada, Shinichi, et al.
Publicado: (2017)

An autopsy case of idiopathic pulmonary fibrosis with remarkable honeycomb cyst expansion
por: Ito, Yu, et al.
Publicado: (2022)

Efficacy of the NCCV Cocktail‐1 vaccine for refractory pediatric solid tumors: A phase I clinical trial
por: Akazawa, Yu, et al.
Publicado: (2019)

A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer
por: OFUJI, KAZUYA, et al.
Publicado: (2014)

Component with abundant immune‐related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis
por: Yagi, Naoki, et al.
Publicado: (2022)

Diagnostic Value of Glypican-3 for Hepatocellular Carcinomas
por: El-Saadany, Sherif, et al.
Publicado: (2018)

Glypican 3 as a Serum Marker for Hepatoblastoma
por: Zhou, Shengmei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_08mp9d7evgmupr7d7n0ri68ua6